
1. Malar J. 2018 Mar 12;17(1):108. doi: 10.1186/s12936-018-2252-2.

The D113N mutation in the RING E3 ubiquitin protein ligase gene is not associated
with ex vivo susceptibility to common anti-malarial drugs in African Plasmodium
falciparum isolates.

Gendrot M(1)(2), Foguim FT(1)(2), Robert MG(1)(2), Amalvict R(1)(2)(3), Mosnier
J(1)(2)(3), Benoit N(1)(2)(3), Madamet M(1)(2)(3), Pradines B(4)(5)(6); French
National Reference Centre for Imported Malaria Study Group.

Collaborators: Augis V, Basset D, Bastien P, Benoit-Vical F, Berry A, Brouqui P, 
Cividin M, Delaunay P, Delhaes L, Drancourt M, Gaillard T, Genin A, Garnotel E,
Javelle E, L'Ollivier C, Leveque M, Malvy D, Marty P, Mechain M, Ménard G, Millet
P, Minodier P, Mottard A, Parola P, Piarroux R, Pomares-Estran C, Receveur M-,
Robin A, Sappa E, Savini H, Simon F, Sterkers Y, Surcouf C, Varlet E, Wolff A.

Author information: 
(1)Unité Parasitologie et entomologie, Département des maladies infectieuses,
Institut de recherche biomédicale des armées, Institut hospitalo-universitaire
(IHU) Méditerranée Infection, 19-21 Boulevard Jean Moulin, 13005, Marseille,
France.
(2)Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, IHU-Méditerranée Infection,
Marseille, France.
(3)Centre national de référence du Paludisme, Institut hospitalo-universitaire
(IHU) Méditerranée Infection, Marseille, France.
(4)Unité Parasitologie et entomologie, Département des maladies infectieuses,
Institut de recherche biomédicale des armées, Institut hospitalo-universitaire
(IHU) Méditerranée Infection, 19-21 Boulevard Jean Moulin, 13005, Marseille,
France. bruno.pradines@gmail.com.
(5)Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, IHU-Méditerranée Infection,
Marseille, France. bruno.pradines@gmail.com.
(6)Centre national de référence du Paludisme, Institut hospitalo-universitaire
(IHU) Méditerranée Infection, Marseille, France. bruno.pradines@gmail.com.

BACKGROUND: Plasmodium falciparum resistance to artemisinin-based combination
therapy has emerged and spread in Southeast Asia. In areas where artemisinin
resistance is emerging, the efficacy of combination is now based on partner
drugs. In this context, the identification of novel markers of resistance is
essential to monitor the emergence and spread of resistance to these partner
drugs. The ubiquitylation pathway could be a possible target for anti-malarial
compounds and might be involved in resistance. Polymorphisms in the E3
ubiquitin-protein ligase (PF3D7_0627300) gene could be associated with decreased 
in vitro susceptibility to anti-malarial drugs.
METHODS: Plasmodium falciparum isolates were collected from patients hospitalized
in France with imported malaria from a malaria-endemic country from January 2015 
to December 2016 and, more particularly, from African French-speaking countries. 
In total, 215 isolates were successfully sequenced for the E3 ubiquitin-protein
ligase gene and assessed for ex vivo susceptibility to anti-malarial drugs.
RESULTS: The D113N mutation in the RING E3 ubiquitin-protein ligase gene was
present in 147 out of the 215 samples (68.4%). The IC50 values for the ten
anti-malarial drugs were not significantly different between the wild-type and
mutant parasites (p values between 0.225 and 0.933). There was no significant
difference in terms of the percentage of parasites with decreased susceptibility 
between the D113 wild-type and the 133N mutated P. falciparum strains (p values
between 0.541 and 1).
CONCLUSION: The present data confirmed the absence of the association between
polymorphisms in the RING E3 ubiquitin-protein ligase gene and the ex vivo
susceptibility to common anti-malarial drugs in African P. falciparum isolates.

DOI: 10.1186/s12936-018-2252-2 
PMCID: PMC5848522
PMID: 29530046  [Indexed for MEDLINE]

